Can HIV Be Eliminated?

3 February 1997

In the Bernard Fields Memorial Lecture at the 4th Conference onRetroviruses and Opportunistic Infections held in Washington DC, USA, David Ho, director of the Aaron Diamond AIDS Research Center in New York City, USA, and a leader in the field of HIV and AIDS research, answered the question "can HIV be eradicated from an infected person?" with the reply: "we don't know."

At the AIDS conference in Vancouver, Canada last year, Dr Ho suggested that if viral replication could be completely suppressed, using a cocktail of protease inhibitors and the older nucleoside drugs, then theoretically one to three years of treatment might eliminate HIV from parts of the body where it is usually found (Marketletter July 22, 1996).

At the Washington DC meeting, Dr Ho presented results from trials with 12 HIV-positive male patients treated with Glaxo Wellcome's Epivir (lamivudine) and Retrovir (zidovudine) plus either Merck's Crixivan (indinavir) or Abbott's Norvir (ritonavir). He found that although patients had no detectable viral RNA in their seminal cells, HIV DNA was present in all patient sperm samples, although it was not determined whether the proviral DNA was infectious.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight